NeuroSense Therapeutics shareholders authorized board to pursue reverse stock split range 1-for-4 to 1-for-40
NRSN•Shareholders approve reverse split authorization
NeuroSense Therapeutics held a special shareholder meeting on Aug. 26, 2026.
Shareholders authorized the board to implement one or more reverse share splits, at an aggregate ratio between 1-for-4 and 1-for-40.
The board will set the exact ratio and any effective date within 12 months; no split has been executed.
Investors also endorsed that no amendment to the articles of association is required for any such reverse split.
